Document is current

Any future updates will be listed below

A new intranasal therapy (MP29‐02*) is more effective than current firstline therapy regardless of season, symptom or severity.

Crossref DOI link: https://doi.org/10.1186/2045-7022-5-S4-P38

Published Online: 2015-06-26

Published Print: 2015-06-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark